PepGenPEPG
About: PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Employees: 76
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 61 [Q2] → 62 (+1) [Q3]
0.14% more ownership
Funds ownership: 77.68% [Q2] → 77.82% (+0.14%) [Q3]
46% less capital invested
Capital invested by funds: $402M [Q2] → $217M (-$185M) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
B of A Securities Tazeen Ahmad 24% 1-year accuracy 7 / 29 met price target | 188%upside $6 | Neutral Maintained | 18 Nov 2024 |
Wedbush Laura Chico 26% 1-year accuracy 16 / 61 met price target | 477%upside $12 | Outperform Maintained | 8 Nov 2024 |
HC Wainwright & Co. Andrew Fein 34% 1-year accuracy 114 / 339 met price target | 1,150%upside $26 | Buy Reiterated | 8 Nov 2024 |
Financial journalist opinion
Based on 13 articles about PEPG published over the past 30 days
